Pylera for Helicobacter pylori Eradication
Pylera (bismuth subcitrate potassium + metronidazole + tetracycline) is a highly effective first-line or rescue therapy for H. pylori eradication, achieving 90-95% eradication rates when combined with a PPI for 10-14 days. 1
Indications
Pylera is indicated for the eradication of H. pylori infection in patients with active duodenal ulcer or a history of duodenal ulcer disease 1. Current guidelines recommend bismuth quadruple therapy (BQT) as a preferred first-line regimen, particularly in areas with high dual resistance to clarithromycin and metronidazole 2. The 2024 ACG guideline specifically recommends BQT for 14 days as the preferred empiric regimen when antibiotic susceptibility is unknown 3.
Recommended Dosage Regimen
Standard dosing:
- Pylera: 3 capsules four times daily (with meals and at bedtime)
- PPI: Omeprazole 20 mg or esomeprazole 40 mg twice daily
- Duration: 10-14 days 1
Each Pylera capsule contains:
- Bismuth subcitrate potassium 140 mg
- Metronidazole 125 mg
- Tetracycline 125 mg 1
The 2021 AGA guideline emphasizes that 14-day durations provide higher eradication success rates compared to shorter durations 4. The Toronto Consensus recommends 14 days for all first-line treatments to maximize first-attempt success 2. Real-world studies demonstrate excellent efficacy with 10-day regimens (90-93% eradication rates) 5, 6, though 14 days is increasingly preferred.
Key dosing considerations:
- Metronidazole dosing should reach 1.5-2 g daily in divided doses when using metronidazole-containing regimens 4
- Capsules must be swallowed whole with a full glass of water
- Take with meals to reduce GI side effects 1
Contraindications
Absolute contraindications 1:
- Concomitant use with methoxyflurane (risk of fatal renal toxicity)
- Concomitant use with disulfiram (within 2 weeks)
- Alcohol consumption during treatment and for 3 days after (disulfiram-like reaction)
- Renal impairment (creatinine clearance <10 mL/min)
- Hypersensitivity to bismuth, metronidazole, tetracycline, or any component
- Pregnancy (tetracycline causes fetal toxicity, tooth discoloration, and skeletal abnormalities)
- Breastfeeding (tetracycline excreted in breast milk)
- Children under 8 years (permanent tooth discoloration and enamel hypoplasia)
Common Adverse Effects
Real-world data from 22,492 patients shows that bismuth quadruple therapy has the highest rate of adverse events (37%) among H. pylori regimens 7. However, most adverse events are mild (57%) and last approximately 7 days, with only 1.3% of patients discontinuing treatment 7.
Most frequent adverse effects:
- Taste disturbance (7%)
- Diarrhea (7%)
- Nausea (6%)
- Abdominal pain (3%)
- Darkening of tongue and/or black stool (common, benign) 1
- Headache
- Dizziness 1
In clinical trials, adverse events occurred in 15.8-56.9% of patients, with most being mild 8, 6. Only 0.08% experienced serious adverse events 7.
Important warnings:
- Central/peripheral nervous system effects: Seizures, peripheral neuropathy (especially with prolonged use or high doses of metronidazole) 1
- Photosensitivity: Tetracycline can cause severe sunburn reactions 1
- Superinfections: Risk of C. difficile-associated diarrhea and candidiasis 1
- Blood dyscrasias: Use caution in patients with existing blood disorders 1
Clinical Efficacy
Multiple real-world studies demonstrate robust eradication rates:
- First-line therapy: 91-96% (per-protocol) 5, 8, 6
- Rescue therapy: 80-93% (intention-to-treat) 5, 6
- No significant difference between treatment-naïve and previously treated patients 6
The regimen maintains high efficacy even in the presence of metronidazole resistance when adequate dosing (1.5-2 g daily) is used with concomitant bismuth therapy 4. Resistance to tetracycline and bismuth remains rare 4.
Key Clinical Pearls
- Compliance is excellent (92-97%) despite the four-times-daily dosing 9, 6
- Longer treatment durations are significantly associated with higher AE incidence but improved eradication 7
- After two failed therapies with confirmed adherence, H. pylori susceptibility testing should be obtained 4
- Inadequate acid suppression contributes to treatment failure; consider high-dose or more potent PPIs 4
- Avoid clarithromycin or levofloxacin-based regimens if prior macrolide or fluoroquinolone exposure 4